









Markets
/
Stocks
/
nasdaq-acog
/

Alpha Cognition Inc

ACOG

View Detailed Chart

9.050USD

0.0000.00%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

144.98MMarket Cap

LossP/E TTM



Alpha Cognition Inc

9.050

0.0000.00%

Overview Company Financials

Financials

Intraday

30m

Today

-0.66%

5 Days

-9.23%

1 Month

-13.52%

6 Months

+53.65%

Year to Date

+53.65%

1 Year

0.00%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 1 analysts

BUY

Current Rating

20.000

Target Price

120.99%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Alpha Cognition Inc

ACOG

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(6)

Neutral(2)

Buy(2)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.380

Neutral

RSI(14)

38.502

Neutral

STOCH(KDJ)(9,3,3)

7.606

Oversold

ATR(14)

0.558

High Vlolatility

CCI(14)

-110.404

Sell

Williams %R

96.970

Oversold

TRIX(12,20)

-0.105

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

9.284

Sell

MA10

9.612

Sell

MA20

10.112

Sell

MA50

9.667

Sell

MA100

7.693

Buy

MA200

6.867

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

Ticker SymbolACOG

CompanyAlpha Cognition Inc

CEOMr. Michael Mcfadden

Websitehttps://www.alphacognition.com/